IP Library Granted Patent US 11,013,721
Granted Patent B2
US 11,013,721 · App. 16/598,874 · Granted May 25, 2021

Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder

Inventors: Uriel Heresco-Levy (Jerusalem, IL); Daniel Javitt (Bardonia, NY)
Assignee: SARAH HERZOG MEMORIAL HOSPITAL EZRAT NASHIM ASSOCIATION
A61K31/42A61K31/137A61K31/496A61K31/519A61K31/551A61K31/554A61K31/5513A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,013,721
App. No.
16/598,874
Granted
May 25, 2021
Kind
B2
Abstract

This invention provides an oral dosage regimen for the treatment of depression, a pharmaceutically acceptable medication dispensing package containing multiple dosage units of medicaments comprising an oral dosage regimen of D-cycloserine for the treatment of depression, a pharmaceutical composition comprising D-cycloserine formulated for oral administration providing a dosage of 1000 mg/day alone or in combination with antidepressant agents and uses thereof.

Claims (16)

1. A method of reducing suicide risk in a patient, comprising:

administering D-cylcoserine at a dosage of 1000 mg/day-2000 mg/day to a patient under treatment for depression and suicidal ideation, wherein said patient is receiving an antidepressant agent selected from the group consisting of tetracyclic antidepressants (TeCA), selective serotine reuptake inhibitors (SSRIs), and serotonin/norepinephrin reuptake inhibitors (SNRIs), wherein said patient is treatment-refractory, and wherein said patient is experiencing side effects from receiving said antidepressant,

wherein prior to administering the combination of the D-cylcoserine and the antidepressant agent, said patient had a glycine plasma level of at least 300 micro molar.

2. The method of claim 1 , wherein said patient suffers from mania.

3. The method of claim 1 , wherein said patient suffers from bipolar disorder.

4. The method of claim 1 , wherein said anti-depressant agent is ketamine.

5. The method of claim 1 , wherein said anti-depressant agent is an anti-NMDA agent.

6. The method of claim 1 , wherein said patient possesses a polymorphism for a GLDC allele.

7. The method of claim 1 , wherein said D-cycloserine is administered to said patient at a dosage of 1100 mg/day-2000 mg/day.

8. The method of claim 1 , wherein either of said antidepressant is administered to said patient at a dosage amount which is considered to be suboptimal for reducing suicide risk in a patient when treating said patient with said antidepressant alone.

9. The method of claim 1 , wherein the administration of said D-cycloserine and said antidepressant to said patient is provided in a single pharmaceutical formulation.

10. The method of claim 1 , wherein the administration of D-cycloserine and said antidepressant to said patient is provided as two separate pharmaceutical formulations.

11. The method of claim 1 , wherein the administration of D-cycloserine to said patient is non-concurrent with the administration to said patient of said antidepressant.

12. The method of claim 1 , wherein said D-cycloserine is administered to said patient at a dosage of 1000 mg/day.

13. The method of claim 1 , wherein said D-cycloserine is administered orally to said patient.

14. The method of claim 1 , wherein said D-cycloserine and said antidepressant agent are combined in a single formulation.

Assignments (3)
SECURITY INTEREST Recorded Sep 20, 2024
From: NRX PHARMACEUTICALS, INC.; HOPE THERAPEUTICS, INC.; NEURORX, INC.
To: ANSON INVESTMENTS MASTER FUND LP; ANSON EAST MASTER FUND LP
Reel/Frame 068647/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2020
From: HERESCO-LEVY, URIAL; JAVITT, DANIEL
To: SEROTECH, LLC
Reel/Frame 052215/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2020
From: SEROTECH, LLC
To: SARAH HERZOG MEMORIAL HOSPITAL EZRAT NASHIM ASSOCIATION
Reel/Frame 051697/0590 →
Continuity (5)
Continuation 15729692 · Oct 11, 2017
Continuation 13982460
Provisional Application 61437700 · Jan 31, 2011
Provisional Application 61494907 · Jun 9, 2011
Related Publication 20200038375A1 · Feb 6, 2020